<DOC>
	<DOCNO>NCT02338050</DOCNO>
	<brief_summary>This phase II , open-label , nonrandomized , prospective study evaluate activity , safety , feasibility administration moxetumomab pasudotox pre-allogeneic hematopoietic cell transplantation ( HCT ) set patient B-lineage Acute Lymphoblastic Leukemia ( ALL ) morphologic complete remission pre-transplant minimal residual disease ( MRD ) &gt; 0.01 % ( detect flow cytometry ) . The primary objective study determine treatment moxetumomab pasudotox MRD positive set able lead MRD negativity ( &lt; 0.01 % flow cytometry ) least 1-log10 reduction MRD prior allogeneic HCT .</brief_summary>
	<brief_title>Moxetumomab Pasudotox ( CAT-8015 , HA22 ) Children With B-lineage Acute Lymphoblastic Leukemia Minimal Residual Disease Prior Allogeneic Hematopoietic Stem Cell Transplantation</brief_title>
	<detailed_description>This Phase 2 study design assess safety , feasibility clinical activity pre-HCT moxetumomab pasudotox patient ALL morphologic CR MRD . It hypothesize subject morphologic complete remission proven minimal residual disease ( MRD ) chemotherapy ALL plan allogeneic HCT receive course moxetumomab pasudotox prior start conditioning show mark reduction elimination detectable MRD moxetumomab pasudotox treatment without adverse impact feasibility safety allogeneic HCT . The primary objective study determine treatment moxetumomab pasudotox MRD positive set able lead MRD negativity ( &lt; 0.01 % flow cytometry ) least 1-log10 reduction MRD prior allogeneic HCT . Secondary objective study include : toxicity profile ( include safety feasibility administration pre-HCT set ability proceed transplant , incidence capillary leak syndrome , hemolytic uremic syndrome post-HCT toxicity ) , comparison quantitative MRD assessment , progression-free survival , overall survival , pharmacokinetic profile , immunogenicity moxetumomab pasudotox , transplant-related mortality , acute chronic graft-versus-host disease ( GVHD ) , relapse .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Neoplasm , Residual</mesh_term>
	<criteria>1 . ≥ 6 month &lt; 25 year age 2 . Histologically confirm diagnosis Blineage ALL . Verification CD22 expression require 3 . Bone marrow morphologic remission ( remission number ) define &lt; 5 % blast ( M1 classification ) perform local institution lab 4 . CNS 1 ( &lt; 5/μL WBCs CSF cytospin negative blast ) 5 . Evidence bone marrow MRD define ≥ 0.01 % flow cytometry perform study central lab 6 . Candidate commit HCT independent participation study , follow requirement : Meets local transplant center eligibility requirement HCT In opinion HCT center ready begin pretransplant conditioning within 6 week trial enrollment medical psychosocial standpoint Has available HCT donor identify cord blood unit . Related unrelated donor , bone marrow , peripheral blood , cord blood stem cell source allow 7 . Adequate organ function include follow : Hepatic function : Total bilirubin &lt; 1.5 × upper limit normal ( ULN ) ( except case subject know Gilbert 's disease : &lt; 5 × ULN ) transaminases ( alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ) &lt; 3 × ULN base age institution specific laboratoryspecific normal range Renal function : Ageadjusted normal serum creatinine require . A 24hour creatinine clearance value &gt; 60 mL/min/1.73 m2 ( updated Schwartz formula nuclear GFR ) must obtain serum creatinine elevate . Hematologic function : Absolute neutrophil count ( ANC ) &gt; 500/μL platelet count &gt; 25,000/μL without transfusion Oxygen saturation rest exercise &gt; 88 % measure pulse oximeter PaO2 &gt; 55 mm Hg without need supplemental oxygen rest activity Serum albumin &gt; 2 g/dL 8 . Performance status : Subjects ≥ 16 year age : Karnofsky ≥ 60 % ( Appendix A ) Subjects &lt; 16 year age : Lansky scale ≥ 60 % ( Appendix A ) Subjects unable walk paralysis , upright wheel chair consider ambulatory purpose calculate performance score 9 . Patients &gt; 18 year age must ability give informed consent accord applicable regulatory local institutional requirement . Legal guardian permission must obtain patient &lt; 18 year age . Pediatric patient include age appropriate discussion order obtain assent 10 . Sexually active female subject childbearing potential male subject sexual partner childbearing potential must agree use contraception 1 . Active extramedullary disease site . ( Note : Definitive therapy know previous site extramedullary disease allow ) 2 . Females breastfeed pregnant 3 . Subjects know 11q23 MLL rearrangement exclude . 4 . Prior therapy : Prior treatment CAT3888 ( BL22 ) , moxetumomab pasudotox ( CAT8015 , HA22 ) , pseudomonasexotoxincontaining compound , antiCD22 direct therapy time past Prior allogeneic autologous HCT adoptive cellular therapy , include Tcell chimeric antigen receptor ( CAR ) therapy Chemotherapy &lt; 2 week prior start study drug follow exception : There time restriction regard prior intrathecal chemotherapy provide complete recovery acute toxic effect Monoclonal antibody therapy &lt; 30 day study enrollment Other investigational agent currently within 30 day prior study enrollment 5 . Subjects absolute contraindication corticosteroid administration 6 . HIV infection ( due increase risk severe infection unknown interaction moxetumomab pasudotox antiretroviral drug ) 7 . Active hepatitis B C infection define seropositivity hepatitis B ( hepatitis B surface antigen [ HbsAg ] ) hepatitis C ( hepatitis C antibody ) elevate liver transaminase ( define ULN per institution normal range ) 8 . Second malignancy nonbasal cell carcinoma skin situ carcinoma cervix , unless tumor treat curative intent least two year previously subject remission 9 . Subject clinical laboratory evidence active DIC 10 . Subject prior history thrombotic microangiopathy HUS within 3 month prior enrollment 11 . History known congenital hypercoagulable condition 12 . Previous lifethreatening anaphylactic reaction prior monoclonal antibodybased immunotherapy component moxetumomab pasudotox formulation 13 . Subjects currently treat high dose estrogen ( high dose define &gt; 0.625mg daily conjugate estrogens equivalent ) within 7 day prior study enrollment</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>24 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>ALL</keyword>
	<keyword>Moxetumomab Pasudotox</keyword>
	<keyword>Moxe</keyword>
	<keyword>CAT-8015 , HA22</keyword>
</DOC>